164 related articles for article (PubMed ID: 20140460)
1. Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease.
Bitzan M; Ouahed JD; Carpineta L; Bernard C; Bell LE
Pediatr Nephrol; 2010 Jun; 25(6):1163-7. PubMed ID: 20140460
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O
J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
[TBL] [Abstract][Full Text] [Related]
4. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant.
Spasojević-Dimitrijeva B; Peco-Antić A; Paripović D; Kruscić D; Krstić Z; Cupić M; Cvetković M; Milosevski-Lomić G; Kostić M
Srp Arh Celok Lek; 2014; 142(1-2):83-8. PubMed ID: 24684038
[TBL] [Abstract][Full Text] [Related]
6. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
Srivastava T; Zwick DL; Rothberg PG; Warady BA
Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
[TBL] [Abstract][Full Text] [Related]
7. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
8. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
[TBL] [Abstract][Full Text] [Related]
9. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
10. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
11. Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study.
Schachtner T; Reinke P
Transpl Infect Dis; 2016 Dec; 18(6):881-888. PubMed ID: 27632022
[TBL] [Abstract][Full Text] [Related]
12. Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study.
Kanzelmeyer NK; Maecker-Kolhoff B; Zierhut H; Lerch C; Verboom M; Haffner D; Pape L
Transpl Int; 2018 Apr; 31(4):367-376. PubMed ID: 28906028
[TBL] [Abstract][Full Text] [Related]
13. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.
Verschuuren EA; Stevens SJ; van Imhoff GW; Middeldorp JM; de Boer C; Koëter G; The TH; van Der Bij W
Transplantation; 2002 Jan; 73(1):100-4. PubMed ID: 11792987
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
Kuriyama T; Kawano N; Yamashita K; Ueda A
J Clin Exp Hematop; 2014; 54(2):149-53. PubMed ID: 25318948
[TBL] [Abstract][Full Text] [Related]
15. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
Sprangers B; Riella LV; Dierickx D
Am J Kidney Dis; 2021 Aug; 78(2):272-281. PubMed ID: 33774079
[TBL] [Abstract][Full Text] [Related]
16. Low viral load post-transplant lymphoproliferative disease localized within the tongue.
Henry DD; Hunger SP; Braylan RC; Dharnidharka VR
Transpl Infect Dis; 2008 Dec; 10(6):426-30. PubMed ID: 18657087
[TBL] [Abstract][Full Text] [Related]
17. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
Blaes AH; Cao Q; Wagner JE; Young JA; Weisdorf DJ; Brunstein CG
Biol Blood Marrow Transplant; 2010 Feb; 16(2):287-91. PubMed ID: 19835968
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review.
Zhu K; Chen J; Chen S
Hematology; 2005 Oct; 10(5):365-70. PubMed ID: 16273722
[TBL] [Abstract][Full Text] [Related]
19. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
Zierhut H; Kanzelmeyer N; Buescher A; Höcker B; Mauz-Körholz C; Tönshoff B; Metzler M; Pohl M; Pape L; Maecker-Kolhoff B
Pediatr Transplant; 2021 Sep; 25(6):e14042. PubMed ID: 34021949
[TBL] [Abstract][Full Text] [Related]
20. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.
Jain AB; Marcos A; Pokharna R; Shapiro R; Fontes PA; Marsh W; Mohanka R; Fung JJ
Transplantation; 2005 Dec; 80(12):1692-8. PubMed ID: 16378063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]